Name: 글로벌 시장 동향
SKU: MD7385
Availability: InStock

보고서 요약(국문)

개요
전 세계 편두통 비강 스프레이 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
편두통 비강 스프레이는 빠르면 15분 안에 편두통 환자에게 증상 완화를 제공할 수 있으며, 특히 메스꺼움과 구토가 있거나 주사를 피하고 싶은 환자에게 유용합니다. 이러한 비강 스프레이는 다양한 유형의 편두통 치료에 가장 일반적으로 사용됩니다. 스프레이는 머리를 똑바로 세운 상태에서 콧구멍에 분사합니다. 그러나 세게 코를 들이쉬거나 머리를 뒤로 젖히면 약물이 목으로 넘어가 경구 투여 약물이 되어 비강을 통한 빠른 전달이라는 장점을 잃게 됩니다.
또한, 비강 스프레이 치료제에는 수마트립탄, 졸미트립탄과 같은 트립탄 계열 약물과 디히드로에르고타민(DHE)과 같은 편두통 특이적 치료제를 포함하는 여러 종류가 있습니다. 트립탄과 DHE는 매우 효과적이지만 혈관 수축을 유발하는 위험이 있으므로 혈관 질환이 있거나 의심되는 사람에게는 사용해서는 안 됩니다. 세 번째 비강 치료 옵션은 비스테로이드성 항염증제(NSAID) 스프레이인 케토롤락 비강 스프레이로, 편두통 염증을 표적으로 하는 약물을 함유하고 있습니다. 이 비강 투여 방식은 편두통 치료에 매우 효과적입니다.
시장 동향: 성장 요인
새로운 기술 발전에 대한 수요 증가
편두통 비강 스프레이 분야의 새로운 기술 발전에 대한 수요 증가가 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 다양한 편두통을 치료하는 데 있어 많은 환자에게 최상의 선택지를 제공하는 혁신적인 비강 스프레이가 출시되고 있습니다. 이러한 기술 발전은 또한 더 나은 환자 결과를 위한 대안 또는 보완 치료 옵션을 제공함으로써 신속한 반응을 통해 편두통 치료와 관련된 미충족 요구를 해결하는 것을 목표로 합니다.

예를 들어, 2023년 3월 10일, 화이자(Pfizer Inc.)는 성인의 전조 증상 유무에 관계없이 편두통의 급성 치료를 위한 최초이자 유일한 칼시토닌 유전자 관련 펩타이드(CGRP) 수용체 길항제 비강 스프레이인 자브즈프레트(ZAVZPRET, 자베지판트)에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. FDA 승인은 편두통의 급성 치료에 대한 자브즈프레트의 효능, 내약성 및 안전성 프로파일을 입증한 두 건의 주요 무작위 이중맹검 위약 대조 연구를 기반으로 합니다.
또한, 발전된 편두통 비강 스프레이는 빠른 작용 발현으로 인해 선호됩니다. 이 약물은 콧구멍에 분사한 후 비점막을 통해 빠르게 흡수되어 경구 약물보다 더 빠른 증상 완화를 제공합니다. 많은 편두통 환자들은 사용이 간편하고 알약을 삼킬 필요가 없기 때문에 비강 스프레이를 선호합니다. 편두통 발작 중에는 알약을 삼키는 것이 어려울 수 있는데, 이러한 이유로 새로운 편두통 비강 스프레이에 대한 수요가 증가하고 있습니다. 많은 제약 회사들이 이러한 비강 스프레이 개발에 집중하고 있습니다.
예를 들어, 임상 단계 바이오제약 회사인 비스타젠(Vistagen)은 2023년 6월 13일 유럽 특허청(EPO)이 자사의 5가지 신속 작용 신경 활성 페린 치료제 중 하나인 PH80 비강 스프레이의 비강 투여를 통한 편두통 치료에 대한 특허를 부여할 의향을 발표했다고 밝혔습니다. 이 특허는 편두통 증상 발현 시 투여하는 치료법과 외상성 뇌손상과 관련된 편두통 치료법도 포함합니다.
또한, 편두통 비강 스프레이 개발은 기존 비강 스프레이 제형에서 나타나는 어지럼증과 같은 부작용을 최소화하는 데 중점을 두고 있습니다. 이러한 부작용을 줄이면 환자 만족도를 높일 수 있습니다. 이러한 발전은 비강 점막을 통한 약물 흡수 효율을 향상시킬 수 있습니다. 약물 전달을 최적화하는 혁신은 편두통 비강 스프레이의 효과를 높일 수 있습니다.
또한, 편두통 유병률 증가, FDA 승인과 같은 규제 기관 승인 증가, 첨단 비강 스프레이 개발을 위한 임상 시험 증가, 편두통 비강 스프레이의 이점에 대한 인식 제고, 그리고 새로운 비강 스프레이 개발의 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.
제약 요인
비강 스프레이 사용과 관련된 합병증, 코피 및 기타 장기적인 부작용과 같은 편두통 비강 스프레이 사용의 부작용, 그리고 편두통 비강 스프레이의 높은 가격은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
세계 편두통 비강 스프레이 시장은 화학 유형, 용량, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.

디히드로에르고타민 비강 스프레이 부문은 편두통 비강 스프레이 시장 점유율의 약 37.9%를 차지했습니다.
디히드로에르고타민 비강 스프레이 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 디히드로에르고타민(DHE) 비강 스프레이는 다양한 유형의 편두통 완화에 효과적인 것으로 잘 알려져 있습니다. 특히 뇌의 혈관을 수축시켜 편두통과 관련된 심한 통증을 완화하는 데 도움을 줍니다. FDA는 환자 치료 효과 향상을 위해 DHE 기반 비강 스프레이를 승인하는 사례가 증가하고 있습니다. 또한, 이러한 제품의 광범위한 사용은 디히드로에르고타민 기반 비강 스프레이에 대한 수요 증가로 이어지고 있습니다.
예를 들어, 2021년 9월 임펠 파마슈티컬스는 성인의 전조 증상 유무에 관계없이 급성 편두통 치료를 위한 트루데사(디히드로에르고타민 메실레이트) 비강 스프레이(분무당 0.725mg)에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 현재 승인된 DHE 기반 약물의 효능은 잘 확립되어 있으며, 급성 편두통 치료의 표준 치료법으로 널리 사용되고 있습니다. DHE는 적절한 혈중 농도에 도달하면 빠른 작용 발현과 최대 48시간 동안 지속되는 효과를 나타내는 것으로 알려져 있습니다.
또한, 폭넓은 가용성, 빠른 효과, 그리고 수용성 덕분에 가장 큰 시장 점유율을 차지하고 있습니다. DHE 비강 스프레이는 비교적 빠른 작용 발현으로 인해 선호됩니다. 다른 편두통 약물보다 빠른 완화를 제공할 수 있어 편두통 발작 중 신속한 통증 완화를 원하는 사람들에게 유용한 선택지입니다. 비강 스프레이는 특히 편두통 발작 중 메스꺼움이나 삼키기 어려움을 겪는 사람들에게 편리한 방식으로 약물을 전달합니다.
예를 들어, 2020년 5월 21일, 시플라(Cipla Limited)는 미국 식품의약국(FDA)으로부터 디히드로에르고타민 메실레이트 비강 스프레이 4mg/mL에 대한 약식 신약 허가 신청(AND) 최종 승인을 경쟁 제네릭 치료제(CGT)로 받았습니다. 지리적 분석
북미 지역은 시장 점유율의 약 40.2%를 차지했습니다.
북미 지역은 주요 업체들의 강력한 입지와 편두통 비강 스프레이의 사용 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 특히 미국을 중심으로 의료기기 회사들을 비롯한 주요 업체들이 다양한 유형의 편두통 치료에 더 나은 효과를 보이는 첨단 비강 스프레이 개발에 적극적으로 나서고 있습니다.
예를 들어, 파다기스(Padagis)는 2021년 11월 16일 12세 이상 편두통 환자 치료를 위한 졸미트립탄 비강 스프레이(Zomig zolmitriptan nasal spray)의 제네릭 버전을 출시했습니다. 파다기스는 졸미트립탄 비강 스프레이 외에도 아젤라스틴, 아젤라스틴/플루티카손 프로피오네이트, 올로파타딘, 수마트립탄, 트리암시놀론 비강 스프레이를 판매하고 있습니다.

또한, 이 지역에서 편두통 유병률이 증가함에 따라 편두통 치료를 위한 비강 스프레이의 사용이 지속적으로 증가하고 있습니다. 예를 들어, 미국 국립보건원(NIH)의 2020년 자료에 따르면, 편두통은 심각한 장애를 유발하는 흔하고 고통스러운 질환입니다. 매년 미국인 7명 중 1명꼴로 편두통을 앓고 있으며, 약 4천만 명이 편두통으로 고통받고 있습니다. 여성의 유병률은 19%, 남성은 9%에 달합니다. 미국에서는 남성보다 여성에게 더 흔하게 나타납니다.
경쟁 환경
편두통 비강 스프레이 시장의 주요 글로벌 업체로는 Pfizer Inc., Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC., Lannett Company, GlaxoSmithKline plc, SteriMax Inc., Assertio Therapeutics, Inc., Cipla Inc., AstraZeneca Plc. 등이 있습니다. 그리고 닥터 레디스 래버러토리스(Dr. Reddy’s Laboratories Ltd.) 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 편두통 비강 스프레이 시장에 상당한 영향을 미쳤습니다. 팬데믹 기간 동안 긴장과 불안, 그리고 집에 머무르는 시간이 늘어나면서 편두통 발생 가능성이 높아졌고, 이는 편두통 치료용 비강 스프레이에 대한 수요 증가로 이어졌습니다. 예를 들어, 미국 국립보건원(NIH)이 2023년에 실시한 연구에 따르면 편두통 환자의 48.6%는 증상이 악화되었고, 15.6%는 호전되었으며, 35.8%는 변화가 없었습니다. 편두통 증상 악화는 봉쇄 기간 동안 집에 머무르는 것과 관련이 있었습니다. 이러한 편두통 환자 수 증가는 편두통 비강 스프레이에 대한 수요 증가를 초래했습니다.

시장 세분화
화학 물질 유형별
• 트립탄 비강 스프레이
• 디히드로에르고타민 비강 스프레이
• 케토롤락 비강 스프레이
• 기타
용량별
• 5mg
• 10mg
• 20mg
• 기타
적용 분야별
• 복합 편두통
• 일반 편두통
• 만성 편두통
• 안구 편두통
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 화학 유형, 용량, 적용 분야, 유통 채널 및 지역별 글로벌 편두통 비강 스프레이 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 편두통 비강 스프레이 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 편두통 비강 스프레이 시장 보고서는 약 69개의 표, 71개의 그림, 187페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global migraine nasal spray market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Migraine nasal sprays can provide relief to migraine patients in as soon as 15 minutes and are especially useful with nausea and vomiting or in those who seek to avoid an injection. These nasal sprays are most commonly used for the treatment of various types of migraine. They are sprayed into the nostril with the head upright. However, vigorous sniffing or tipping the head backward puts the medicine down the throat, turning a spray into an oral medication and losing the advantages of rapid nasal delivery.
Moreover, there are several categories of nasal spray treatment, including nasal triptans such as sumatriptan and zolmitriptan and dihydroergotamine (DHE) which contain migraine-specific treatment. Triptans and DHE are highly effective but it has some risk factors by causing blood vessel narrowing and should not be used in people with known or suspected vascular disease. A third nasal option is a non-steroidal anti-inflammatory (NSAID) spray, nasal ketorolac, containing medicine targeting migraine inflammation. This nasal delivery is very effective for treating migraine.
Market Dynamics: Drivers
Increasing demand for novel advancements
The increasing demand for novel advancements in migraine nasal sprays is expected to drive the market over the forecast period. The novel advanced nasal spray is launched which offers the best options to many patients to treat various migraines. The advancements also aim to address the unmet needs associated with the treatment of migraines with rapid response by providing alternative or complementary treatment options for better patient outcomes.
For instance, on March 10, 2023, Pfizer Inc. cleared the U.S. Food and Drug Administration (FDA) approval of ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. The FDA approval is based on two pivotal randomized, double-blind, placebo-controlled studies that established the efficacy, tolerability and safety profiles of ZAVZPRET for the acute treatment of migraine.
Moreover, advanced migraine nasal sprays are favored for their rapid onset of action. The medication can be absorbed quickly through the nasal mucosa after spraying it into the nostrils, offering faster relief compared to oral medications. Many migraine patients most commonly prefer nasal sprays because they are easy to use and do not require swallowing a pill, which can be challenging during a migraine attack, this increases the demand for novel advancements in migraine nasal sprays. Many pharmaceutical companies focus on developing these nasal sprays.
For instance, on June 13, 2023, Vistagen, a clinical-stage biopharmaceutical company released that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company’s five rapid-onset investigational neuroactive pherine therapeutics. The patent claims also include treatment administered at the onset of migraine symptoms and treatment of migraines associated with traumatic brain injury.
Additionally, advancements in migraine nasal sprays mainly focus on minimizing side effects, such as dizziness, which are associated with some existing nasal spray formulations. Reducing these side effects can improve patient satisfaction. These advancements can enhance the efficiency of drug absorption through the nasal mucosa. Innovations that optimize drug delivery can make migraine nasal sprays more effective.
Further, the increasing prevalence of migraine, rising regulatory approvals such as FDA approvals, increasing clinical trials for the development of advanced nasal sprays, increasing awareness about the advantages of nasal sprays for migraine and advancements in the development of novel nasal sprays are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the use of nasal sprays, adverse effects of using migraine nasal sprays such as bleeding from the nose and other long-term effects, and the high cost of the migraine nasal sprays are expected to hamper the market.
Segment Analysis
The global migraine nasal spray market is segmented based on chemical type, dosage, application, distribution channel and region.
The dihydroergotamine nasal sprays segment accounted for approximately 37.9% of the migraine nasal spray market share
The dihydroergotamine nasal spray segment is expected to hold the largest market share over the forecast period. Dihydroergotamine (DHE) nasal sprays are very well known for their effectiveness in providing relief from the various types of migraines. They especially work by constricting blood vessels in the brain, which can help alleviate the severe pain associated with migraines. The FDA approvals are increasing for approving the DHE-based nasal sprays for better patient outcomes. In addition, their wide adoption also increases the demand for the dihydroergotamine-based nasal spray.
For instance, in September 2021, Impel Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval for Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. The efficacy of currently approved DHE-based medications is well-established and they are widely used as part of the standard of care for the acute treatment of migraine. DHE, when reaching satisfactory systemic blood levels, is known to have fast onset and lasting effects for up to 48 hours.
Further, their wide availability, rapid effectiveness and acceptability help to hold the largest market share. DHE nasal sprays are favored for their relatively quick onset of action. They can provide faster relief than other migraine medications, making them a valuable option for individuals seeking rapid pain relief during a migraine attack. The nasal spray delivers the medication in a convenient way, especially for individuals who may experience nausea or difficulty swallowing during a migraine attack.
For instance, on May 21, 2020, Cipla Limited received final approval for its Abbreviated New Drug Application for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (FDA) with a Competitive Generic Therapy (CGT) designation.
Geographical Analysis
North America accounted for approximately 40.2% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of the migraine nasal sprays. North America especially the United States is known for its strong presence of major players such as medical device companies which are actively focusing on developing advanced nasal sprays that show better results in treating various types of migraines.
For instance, on November 16, 2021, Padagis launched its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. In addition to the zolmitriptan nasal spray, Padagis markets azelastine, azelastine/fluticasone propionate, olopatadine, sumatriptan, and triamcinolone nasal sprays.
Furthermore, the increasing prevalence of migraine in the region is continuously increasing the adoption of migraine nasal sprays for treatment. For instance, according to the National Institute of Health (NIH), 2020, Migraine headache is a common, debilitating disease that causes significant disability. It affects nearly 1 in 7 Americans each year, with an estimated 40 million people suffering from migraine headaches. Its prevalence is as high as 19% for females and 9% for males. It is more commonly seen in females than males in the United States.
Competitive Landscape
The major global players in the migraine nasal spray market include Pfizer Inc., Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC., Lannett Company, GlaxoSmithKline plc, SteriMax Inc., Assertio Therapeutics, Inc., Cipla Inc., AstraZeneca Plc. and Dr. Reddy’s Laboratories Ltd. among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global migraine nasal spray market. During the pandemic, due to the tension and anxiety and the people staying at home increased the chances of migraines, which further increased the demand for nasal sprays for the treatment. For instance, according to the study conducted by the National Institute of Health (NIH) in 2023, the results show that 48.6% of migraine patients experienced worsened symptoms, 15.6% improved, and 35.8% remained unchanged. Worsening migraine symptoms were associated with staying at home during the lockdown. This increased number of migraine cases increased the demand for migraine nasal sprays.
Market Segmentation
By Chemical Type
• Triptan Nasal Sprays
• Dihydroergotamine Nasal Sprays
• Nasal Ketorolac
• Others
By Dosage
• 5 mg
• 10 mg
• 20 mg
• Others
By Application
• Complicated Migraine
• Common Migraine
• Chronic Migraine
• Ocular Migraine
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global migraine nasal spray market segmentation based on chemical type, dosage, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of migraine nasal spray market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global migraine nasal spray market report would provide approximately 69 tables, 71 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Chemical Type
3.2. Snippet by Dosage
3.3. Snippet by Application
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Novel Advancements
4.1.2. Restraints
4.1.2.1. Complications Associated with the Migraine Nasal Sprays
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Chemical Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chemical Type
7.1.2. Market Attractiveness Index, By Chemical Type
7.2. Triptan Nasal Sprays*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dihydroergotamine Nasal Sprays
7.4. Nasal Ketorolac
7.5. Others
8. By Dosage
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
8.1.2. Market Attractiveness Index, By Dosage
8.2. 5 mg*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. 10 mg
8.4. 20 mg
8.5. Others
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Complicated Migraine*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Common Migraine
9.4. Chronic Migraine
9.5. Ocular Migraine
9.6. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chemical Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chemical Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chemical Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chemical Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chemical Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Impel Pharmaceuticals Inc.
13.3. Upsher-Smith Laboratories, LLC.
13.4. Lannett Company
13.5. GlaxoSmithKline plc
13.6. SteriMax Inc.
13.7. Assertio Therapeutics, Inc.
13.8. Cipla Inc.
13.9. AstraZeneca Plc.
13.10. Dr. Reddy’s Laboratories Ltd.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC., Lannett Company, GlaxoSmithKline plc, SteriMax Inc., Assertio Therapeutics, Inc., Cipla Inc., AstraZeneca Plc., Dr. Reddy’s Laboratories Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Migraine Nasal Spray Market Value, By Chemical Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Migraine Nasal Spray Market Value, By Dosage, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Migraine Nasal Spray Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Migraine Nasal Spray Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Migraine Nasal Spray Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Migraine Nasal Spray Market Value, By Chemical Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Migraine Nasal Spray Market Value, By Chemical Type, 2021-2030 (US$ Million)

Table 8 Global Migraine Nasal Spray Market Value, By Dosage, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Migraine Nasal Spray Market Value, By Dosage, 2021-2030 (US$ Million)

Table 10 Global Migraine Nasal Spray Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Migraine Nasal Spray Market Value, By Application, 2021-2030 (US$ Million)

Table 12 Global Migraine Nasal Spray Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Migraine Nasal Spray Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Migraine Nasal Spray Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Migraine Nasal Spray Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Migraine Nasal Spray Market Value, By Chemical Type, 2021-2030 (US$ Million)

Table 17 North America Migraine Nasal Spray Market Value, By Dosage, 2021-2030 (US$ Million)

Table 18 North America Migraine Nasal Spray Market Value, By Application, 2021-2030 (US$ Million)

Table 19 North America Migraine Nasal Spray Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Migraine Nasal Spray Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Migraine Nasal Spray Market Value, By Chemical Type, 2021-2030 (US$ Million)

Table 22 South America Migraine Nasal Spray Market Value, By Dosage, 2021-2030 (US$ Million)

Table 23 South America Migraine Nasal Spray Market Value, By Application, 2021-2030 (US$ Million)

Table 24 South America Migraine Nasal Spray Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Migraine Nasal Spray Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Migraine Nasal Spray Market Value, By Chemical Type, 2021-2030 (US$ Million)

Table 27 Europe Migraine Nasal Spray Market Value, By Dosage, 2021-2030 (US$ Million)

Table 28 Europe Migraine Nasal Spray Market Value, By Application, 2021-2030 (US$ Million)

Table 29 Europe Migraine Nasal Spray Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Migraine Nasal Spray Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Migraine Nasal Spray Market Value, By Chemical Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Migraine Nasal Spray Market Value, By Dosage, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Migraine Nasal Spray Market Value, By Application, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Migraine Nasal Spray Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Migraine Nasal Spray Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Migraine Nasal Spray Market Value, By Chemical Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Migraine Nasal Spray Market Value, By Dosage, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Migraine Nasal Spray Market Value, By Application, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Migraine Nasal Spray Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Pfizer Inc.: Overview

Table 41 Pfizer Inc.: Product Portfolio

Table 42 Pfizer Inc.: Key Developments

Table 43 Impel Pharmaceuticals Inc.: Overview

Table 44 Impel Pharmaceuticals Inc.: Product Portfolio

Table 45 Impel Pharmaceuticals Inc.: Key Developments

Table 46 Upsher-Smith Laboratories, LLC.: Overview

Table 47 Upsher-Smith Laboratories, LLC.: Product Portfolio

Table 48 Upsher-Smith Laboratories, LLC.: Key Developments

Table 49 Lannett Company: Overview

Table 50 Lannett Company: Product Portfolio

Table 51 Lannett Company: Key Developments

Table 52 GlaxoSmithKline plc: Overview

Table 53 GlaxoSmithKline plc: Product Portfolio

Table 54 GlaxoSmithKline plc: Key Developments

Table 55 SteriMax Inc.: Overview

Table 56 SteriMax Inc.: Product Portfolio

Table 57 SteriMax Inc.: Key Developments

Table 58 Assertio Therapeutics, Inc.: Overview

Table 59 Assertio Therapeutics, Inc.: Product Portfolio

Table 60 Assertio Therapeutics, Inc.: Key Developments

Table 61 Cipla Inc.: Overview

Table 62 Cipla Inc.: Product Portfolio

Table 63 Cipla Inc.: Key Developments

Table 64 AstraZeneca Plc.: Overview

Table 65 AstraZeneca Plc.: Product Portfolio

Table 66 AstraZeneca Plc.: Key Developments

Table 67 Dr. Reddy’s Laboratories Ltd.: Overview

Table 68 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 69 Dr. Reddy’s Laboratories Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 2 Global Migraine Nasal Spray Market Share, By Chemical Type, 2022 & 2030 (%)

Figure 3 Global Migraine Nasal Spray Market Share, By Dosage, 2022 & 2030 (%)

Figure 4 Global Migraine Nasal Spray Market Share, By Application, 2022 & 2030 (%)

Figure 5 Global Migraine Nasal Spray Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Migraine Nasal Spray Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Migraine Nasal Spray Market Y-o-Y Growth, By Chemical Type, 2022-2030 (%)

Figure 8 Triptan Nasal Sprays Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 9 Dihydroergotamine Nasal Sprays Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 10 Nasal Ketorolac Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 11 Others Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 12 Global Migraine Nasal Spray Market Y-o-Y Growth, By Dosage, 2022-2030 (%)

Figure 13 5 mg Dosage in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 14 10 mg Dosage in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 15 20 mg Dosage in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 16 Others Dosage in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 17 Global Migraine Nasal Spray Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 18 Complicated Migraine Application in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 19 Common Migraine Application in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 20 Chronic Migraine Application in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 21 Ocular Migraine Application in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 22 Others Application in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 23 Global Migraine Nasal Spray Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 24 Hospital Pharmacies Distribution Channel in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 25 Retail Pharmacies Distribution Channel in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 26 Online Pharmacies Distribution Channel in Global Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 27 Global Migraine Nasal Spray Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 29 Asia-Pacific Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 30 Europe Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 31 South America Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 32 Middle East and Africa Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 33 North America Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 34 North America Migraine Nasal Spray Market Share, By Chemical Type, 2022 & 2030 (%)

Figure 35 North America Migraine Nasal Spray Market Share, By Dosage, 2022 & 2030 (%)

Figure 36 North America Migraine Nasal Spray Market Share, By Application, 2022 & 2030 (%)

Figure 37 North America Migraine Nasal Spray Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38 North America Migraine Nasal Spray Market Share, By Country, 2022 & 2030 (%)

Figure 39 South America Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 40 South America Migraine Nasal Spray Market Share, By Chemical Type, 2022 & 2030 (%)

Figure 41 South America Migraine Nasal Spray Market Share, By Dosage, 2022 & 2030 (%)

Figure 42 South America Migraine Nasal Spray Market Share, By Application, 2022 & 2030 (%)

Figure 43 South America Migraine Nasal Spray Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44 South America Migraine Nasal Spray Market Share, By Country, 2022 & 2030 (%)

Figure 45 Europe Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 46 Europe Migraine Nasal Spray Market Share, By Chemical Type, 2022 & 2030 (%)

Figure 47 Europe Migraine Nasal Spray Market Share, By Dosage, 2022 & 2030 (%)

Figure 48 Europe Migraine Nasal Spray Market Share, By Application, 2022 & 2030 (%)

Figure 49 Europe Migraine Nasal Spray Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Europe Migraine Nasal Spray Market Share, By Country, 2022 & 2030 (%)

Figure 51 Asia-Pacific Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 52 Asia-Pacific Migraine Nasal Spray Market Share, By Chemical Type, 2022 & 2030 (%)

Figure 53 Asia-Pacific Migraine Nasal Spray Market Share, By Dosage, 2022 & 2030 (%)

Figure 54 Asia-Pacific Migraine Nasal Spray Market Share, By Application, 2022 & 2030 (%)

Figure 55 Asia-Pacific Migraine Nasal Spray Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 56 Asia-Pacific Migraine Nasal Spray Market Share, By Country, 2022 & 2030 (%)

Figure 57 Middle East & Africa Migraine Nasal Spray Market Value, 2021-2030 (US$ Million)

Figure 58 Middle East & Africa Migraine Nasal Spray Market Share, By Chemical Type, 2022 & 2030 (%)

Figure 59 Middle East & Africa Migraine Nasal Spray Market Share, By Dosage, 2022 & 2030 (%)

Figure 60 Middle East & Africa Migraine Nasal Spray Market Share, By Application, 2022 & 2030 (%)

Figure 61 Middle East & Africa Migraine Nasal Spray Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 62 Pfizer Inc.: Financials

Figure 63 Impel Pharmaceuticals Inc.: Financials

Figure 64 Upsher-Smith Laboratories, LLC.: Financials

Figure 65 Lannett Company: Financials

Figure 66 GlaxoSmithKline plc: Financials

Figure 67 SteriMax Inc.: Financials

Figure 68 Assertio Therapeutics, Inc.: Financials

Figure 69 Cipla Inc.: Financials

Figure 70 AstraZeneca Plc.: Financials

Figure 71 Dr. Reddy’s Laboratories Ltd.: Financials

세계 편두통 비강 스프레이 시장 – 2023-2030

Global Migraine Nasal Spray Market - 2023-2030